TB-500

TB-500 (also known as Thymosin Beta-4 fragment, Tβ4) is a prominently researched experimental compound classified strictly within the Thymosin Beta-4 Fragment framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair. with a documented biological half-life of roughly 2 hours, In preclinical investigative trials and independent academic studies, researchers utilizing TB-500 have documented significant, quantifiable biological outcomes, primarily focusing on muscle/tissue repair, flexibility, injury recovery. Typical research protocols investigate administering 2500 to 2500mcg via subq pathways 2x/wk. However, it is critically important to understand that while TB-500 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.